The sales price is based on proven revenue and likely future revenue. That cannot be determined now. There is a lag time from when a pharma commits to use Lympro and when they submit their plan to the FDA for the trial, and then when they actually use Lympro in their trial and finally pay us. So initially, even though Lympro will stir up great interest from pharma, and even commitments from them, the revenue will not materialize over night.

That's why I think Gerald will get a much bigger sales price a year or so from now. LymPro's value will be so much larger then than it is now.